867200 | Sustainable Squalene
(6E,10E,14E,18E)-2,6,10,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaene
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
Sustainable Squalene
(6E,10E,14E,18E)-2,6,10,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaene
Non-shark derived, engineered by synthetic biology. Our Squalene has superior purity, naturally setting it apart on the market.
An innovative alternative to shark-derived squalene using synthetic biology
There is a significant need for a highly purified alternative to shark-derived squalene to meet the requirements of the vaccine industry. To mitigate the devastating impact on deep-sea shark populations, we are proud to offer a sustainably sourced, sugar-derived Squalene carrying the same benefits as shark-derived squalene.
What is squalene? And why is there a strong need for vaccine formulations?
Squalene is an organic compound with powerful bioactive properties. As a naturally occurring oil, squalene has successfully been used in various emulsion-based vaccine adjuvant formulations. They do not only initiate potent innate and adaptive immune responses but also have established safety records. This has ignited interest in squalene and inspired the search for more sustainable alternatives.
Squalene-based emulsions
Squalene-based emulsions are used in licensed seasonal and pandemic influenza vaccines. Furthermore, there are clinical development projects for prophylactic vaccines ongoing, for example those against tuberculosis, shingles, schistosomiasis, HIV and other severe diseases, combining squalene with a TLR4 agonist in their emulsion adjuvant.
C30H50
C 87.73%, H 12.27%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by Bioz- Certificate of Analysis (Lot No. 867200O-500MG-A-010 and 7183OPA010)
- Certificate of Analysis (Lot No. 867200O-100MG-A-010 and 7183OLA010)
- Certificate of Analysis (Lot No. 867200O-1G-A-010 and 7183OQA010)
- Certificate of Analysis (Lot No. 867200O-1G-B-010 and 7183OQB010)
